Fig. 8.

OX6 immunoreactive microglial cells in the substantia nigra compacta 4 weeks after injection of saline, or empty AAV9 vectors (AAV9-Ф), or AAV9 expressing human WT α-syn, or AAV9 expressing human A53T mutated α-syn in rats not treated or treated with the AT1 antagonist candesartan (CAND) or telmisartan (TELM). Representative photomicrographs of the substantia nigra compacta of different groups of rats are shown in (c)–(i). The estimated number of OX6-ir cells in the substantia nigra of the different experimental groups is shown in (a) and (b). The microglial cells are shown as % of that observed in controls (i.e., saline-injected rats), and data are means ± SEM. ^*p < 0.05 relative to the group treated with saline, ^#p < 0.05 relative to the AAV9-Ф-injected group, ^&p < 0.05 relative to the group injected with AAV9 expressing human WT α-syn (a) or expressing human A53T mutated α-syn (b). One-way ANOVA and Holm–Sidak post hoc test. Scale bar = 100 μm. Abbreviations: ANOVA = analysis of variance; SEM = standard error of the mean; Ф = empty-null